Institutional members access full text with Ovid®

Foscarnet-related Hypercalcemia During CMV Treatment in an Infant With SCID: A Case Report and Review of Literature

Rabinowicz, Shira MD; Somech, Raz MD, PhD; Yeshayahu, Yonatan MD, MHA

Journal of Pediatric Hematology/Oncology: April 2017 - Volume 39 - Issue 3 - p e173–e175
doi: 10.1097/MPH.0000000000000682
Online Articles: Clinical and Laboratory Observations

Foscarnet is a main treatment for disseminated cytomegalovirus infection in immunocompromised patients. One of its documented side effects is hypocalcemia. Hypercalcemia, in contrast, was described anecdotally before, almost exclusively in adults with human immunodeficiency virus infection or posttransplantation. We describe a case of severe hypercalcemia during foscarnet treatment in an infant with IL-7 Rα deficient severe combined immunodeficiency, resolved after treatment cessation. We speculate that this unusual side effect is caused by foscarnet binding to the inorganic matrix of bone.

*Pediatric Department A

§Pediatric Endocrinology Unit, Sheba Medical Center, Edmond and Lily Safra Children’s Hospital, Tel Hashomer

Sackler Faculty of Medicine, Tel Aviv University

Cancer Research Center, Pediatric Immunology Service, Jeffrey Modell Foundation (JMF) Center, Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel

The authors declare no conflict of interest.

Reprints: Yonatan Yeshayahu, MD, MHA, Pediatric Endocrinology Unit, Sheba Medical Center, Edmond and Lily Safra Children’s Hospital, Tel Hashomer, 52621, Israel (e-mail: Yonatan.Yeshayahu@sheba.health.gov.il).

Received January 30, 2016

Accepted September 28, 2016

Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.